No Data
No Data
Express News | Nanmo Biological: Shareholder Kang Jun Ningyuan plans to reduce shareholding by no more than 1.90% of the company's shares.
Nanmo Biology: third quarter report 2024
Third Quarter Report 2024
The downstream encountered a cold impact on earnings. Nangmod Biological plans to increase production capacity utilization rate, with overseas as a "key expansion area". | Focus on the earnings conference
①Due to the unfavorable impact of downstream industrial clients' investment and financing, Namo Biotechnology's performance has been under continued pressure in recent years. Chairman Fei Jian revealed that the overall utilization rate of domestic production capacity is close to 80%, and will further improve the capacity utilization rate in the future; ②In the first half of 2024, the proportion of overseas business income has already increased to 14%. Fei Jian openly stated that overseas expansion is a key focus, and in the second half of the year, the overseas business development team will be further optimized.
Express News | Star Market Market Summary: Biopharmaceuticals and lithium battery sectors performed poorly, while semiconductor sector had mixed gains and losses.
Nanmo Biotech (688265.SH): Shareholders intend to inquire about the transfer of 1.15% of the shares.
Gelonghui, September 9th, Nanmo Biotechnology (688265.SH) announced that the shareholders participating in the pre-IPO shareholder inquiry transfer of Nanmo Biotechnology are Shenzhen Qianhai Rongfeng Investment Partnership Enterprise (Limited Partnership); the total number of shares to be transferred by the transferor is 896,581 shares, accounting for 1.15% of the total share capital of Nanmo Biotechnology; this inquiry transfer is a non-public transfer, and will not be conducted through centralized bidding or block trading, and does not constitute a secondary market share sale. The transferee shall not transfer the shares acquired through the inquiry transfer within 6 months after the transfer.
No Data